Johnson & Johnson has lost another round in its patent defence for prostate cancer blockbuster Zytiga, raising the possibility that generics could launch in the coming days. A US district court in ...

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs). The FDA ...